GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Solanbridge Group SLNX · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Price performance

Chart by TradingView, with its own licensed prices

Solanbridge Group — daily SLNX Delayed
Market value
$3,358
Last close × shares
Volume
1.3m
Shares, 30 Oct 2026

About Solanbridge Group

Its shares trade under the ticker SLNX. It has been listed since 29 June 2007. In the fiscal year to 31 December 2014, it reported revenue of $229,072 and a net loss of $2,149. At that date it held total assets of $53,320 and shareholders' equity of −$203,484.

Solanbridge Group Inc. is a biotechnology company, which engages in the research, development, and production of nutraceutical and cosmetic products. The company is headquartered in Spring, Texas. The company went IPO on 2007-06-29. The firm is a holding company. The firm is looking to expand into the medical marijuana industry by developing a commercial grower's license in the Province of Nova Scotia, Canada and developing cannbidiol (CBD) infused products in Nevada, California and Colorado. The firm focuses on providing a product that will help physicians and patients in managing health, and it will be available only to Canadians holding a legal license to possess medical marijuana. Solanbridge Group Nova Scotia, Inc. is a subsidiary of the Company.

Figures and description from our data supplier, not checked against the company's own report.

More about Solanbridge Group →

Latest on Solanbridge Group

Our reporting

We have not reported on Solanbridge Group yet.

Other N/A listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Solanbridge Group's ticker?

Solanbridge Group trades as SLNX on its US listing, under ISIN US83412T1043.

What was Solanbridge Group's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.